Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | PHASE1 | COMPLETED | 16 | — | — | Sep 28, 2020 | Mar 21, 2022 | Nov 15, 2022 | 5 | United States |
Dose limiting toxicities will be evaluated through the first cycle
The MTD and/or OBD will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome
The RP2D will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome
| Arm | Type | Description |
|---|---|---|
| PRT1419 | EXPERIMENTAL | PRT1419 will be administered orally |
| Name | Type | Description |
|---|---|---|
| PRT1419 | DRUG | PRT1419 will be administered orally |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Adequate organ function (bone marrow, hepatic, renal, cardiovascular) * Left ventricular ejection fraction of ≥50% * Female patients of childbearing potential must have a negative pregnancy test within 7 day...